AUTHOR INDEX TO VOLUME 2

Alonso, F. G., 245
Armenian, H. K., 101

Bakke, O. M., 245
Barnett, P. S., 233
Barnett, S. T., 241
Bromberg, M. J., 79
Brown, M. S., 15

Carey, R., 115
Cato, A., 1, 3, 89, 211
Chamieh, M. A., 101
Chen, K., 233
Cocchetto, D. M., 3

Dalton, M., 31
Darwish, M. J., 101

Edlavitch, S. A., 179

Faich, G., 75

Goldberg, M. R., 215
Gorman, M. R., 227
Griffith, R. W., 141

Hall, D., 83
Harwood, F., 241

Jacob, L., 115
Jick, H., 227

Kelley, E. P., 233

Lai, A., 53
Lasagna, L., 7
Levy, D. I., 145
Lineberry, C. G., 89
Lyon, G., 31

McAllister, R. G., 11
Miller, L., 31
Myers, M. W., 47

Novack, G. D., 233

Offen, W. W., 215

Perkins, J. G., 31
Plachetka, J. R., 207
Pledger, G., 83

Ray, W. A., 67
Reidenberg, M. M., 10
Richard, B. W., 15
Ritchie-Norris, D., 253
Rockhold, F. W., 215

Sanders, S. W., 135
Stang, P., 53
Strickler, S. W., 153
Strom, B. L., 161

Thompson, L., 29
Tilson, H., 65, 89
Tolman, K. G., 135

Vestal, R., 31

Walker, A. W., 227
Wallach, R. W., 227
Weakly, J. N., 89
Weisweiler, P. S., 233
Worth, J., 169

Journal of Clinical Research and Drug Development 2, 263 (1988)

© 1988 Associates of Clinical Pharmacology

Published by Elsevier Science Publishing Co., Inc.
655 Avenue of the Americas, New York, NY 10010

0889-5813/88/$3.50

SUBJECT INDEX TO VOLUME 2

ABSTRACTS
Abstracts; Associates of Clinical Pharmacology Meeting, December 1–5, 1987, Vail, Colorado, 55
ACP Spring 1988 Poster Abstracts: April 19–23, 1988, Seattle, Washington, 125
Abstracts: 4th International Conference on Pharmacoepidemiology, Sept. 6–9, 1988, University of Minnesota, Minneapolis, 181

ADVERSE EFFECTS
Steroids, Diabetes, Analgesics, and the Risk of Cataract: Lessons from the Epidemiology of Cataract Extraction, 227

ADVISORY COMMITTEE SYSTEM
Advisory Committees and the Drug Approval Process, 15
FDA Advisory Committees: Stage, Pedagogy, Opprobrium, 29

AIDS
When and at What Stage Should a New Therapy for AIDS Be Evaluated in a Randomized Clinical Trial, 47
Ethical Dilemma of Placebo-Controlled Trials in Life-Threatening Illnesses: Azidothymidine (AZT) for the Treatment of AIDS, 145

AMINOTRANSFERASE ELEVATIONS
Application of Epstein-Barr Antibody Studies to Etiologic Differentiation of Aminotransferase Elevations During Controlled Clinical Trials, 135

ANALGESICS
Steroids, Diabetes, Analgesics, and the Risk of Cataract: Lessons from the Epidemiology of Cataract Extraction, 227

ANIMAL TOXICOLOGY
Carcinogenic Potential of Marketed Drugs, 141

APLASTIC ANEMIA
Use of the Lognormal Distribution to Study the Time of Occurrence of Drug-Induced Diseases, 101

ARCHIVING OF STUDY RECORDS
Document Filing System for Clinical Research, 153

AUDIT-ORIENTED FILING SYSTEM
Document Filing System for Clinical Research, 153

AZT
Ethical Dilemma of Placebo-Controlled Trials in Life-Threatening Illnesses: Azidothymidine (AZT) for the Treatment of AIDS, 145

CARCINOGENITY
Carcinogenic Potential of Marketed Drugs, 141

CATARACT
Steroids, Diabetes, Analgesics, and the Risk of Cataract: Lessons from the Epidemiology of Cataract Extraction, 227

CLINICAL ORGANIZATION
A Geocentric Approach to Sponsor Conducted Clinical Trials, 115

CLINICAL R&D
A Geocentric Approach to Sponsor Conducted Clinical Trials, 115

CLINICAL SUPPLY
Electronic Drug Accountability: A Trial Management Tool, 169

CLINICAL TRIALS
Early Termination of Clinical Trials, 83
A Geocentric Approach to Sponsor Conducted Clinical Trials, 115
Application of Epstein-Barr Antibody Studies to Etiologic Differentiation of Aminotransferase Elevations During Controlled Clinical Trials, 135
Integrating Pharmacoepidemiology into the Design and Conduct of Clinical Trials, 161
Factorial Design: An Approach to the Assessment of Therapeutic Drug Interactions in Clinical Trials, 215

Journal of Clinical Research and Drug Development 2, 265–268 (1988)

© 1988 Associates of Clinical Pharmacology

Published by Elsevier Science Publishing Co., Inc.
655 Avenue of the Americas, New York, NY 10010

0889-5813/88/$3.50

COLITIS
Use of the Lognormal Distribution to Study the Time of Occurrence of Drug-Induced Diseases, 101

COMFORT
Comparative Comfort of Flurbiprofen Solution and Indomethacin Suspension Eyedrops, 233

COMMENTARY
Commentary on "Serum Concentrations and Adverse Effects of Vancomycin in Pediatric Patients" by Milap Nahata and Jacob Kammer, *Journal of Clinical Research and Drug Development* 1:307–312, 53

DIABETES
Steroids, Diabetes, Analgesics, and the Risk of Cataract: Lessons from the Epidemiology of Cataract Extraction, 227

DOCUMENT FILING SYSTEM
Document Filing System for Clinical Research, 153

DOCUMENT STORAGE
Document Filing System for Clinical Research, 153

DOSE EFFECT/TIME ACTION
Delays in the Drug Approval Process: Recent Trends, 31

DRUG APPROVAL PROCESS
Advisory Committees and the Drug Approval Process, 15
Delays in the Drug Approval Process: Recent Trends, 31

DRUG DEVELOPMENT
Carcinogenic Potential of Marketed Drugs, 141
Drug Development in Spain: Towards a Brighter Future? 245

DRUG-INDUCED DISEASES
Use of the Lognormal Distribution to Study the Time of Occurrence of Drug-Induced Diseases, 101

DRUG INTERACTION
Factorial Design: An Approach to the Assessment of Therapeutic Drug Interactions in Clinical Trials, 215

DRUG INVENTORY
Electronic Drug Accountability: A Trial Management Tool, 169

DRUG LABELING
Carcinogenic Potential of Marketed Drugs, 141

DRUG REGULATION
Advisory Committees and the Drug Approval Process, 15

DRUG SPONSOR
Advisory Committees and the Drug Approval Process, 15

DRUG TOLERANCE
Use of the Lognormal Distribution to Study the Time of Occurrence of Drug-Induced Diseases, 101

DRUG TOXICITY
Carcinogenic Potential of Marketed Drugs, 141

EDITORIALS
The First Year, 1
A Giant Step for Pharmacoepidemiology, 65
Changing of the Guard, 211

ELECTRONIC DRUG ACCOUNTABILITY
Electronic Drug Accountability: A Trial Management Tool, 169

EPIDEMIOLOGY
Epidemiology in Pharmaceutical Liability Litigation: Sword, Shield, or Booby Trap? 79
Steroids, Diabetes, Analgesics, and the Risk of Cataract: Lessons from the Epidemiology of Cataract Extraction, 227

EPSTEIN-BARR VIRUS
Application of Epstein-Barr Antibody Studies to Etiologic Differentiation of Aminotransferase Elevations During Controlled Clinical Trials, 135

ETHICAL CLINICAL RESEARCH
Ethical Dilemma of Placebo-Controlled Trials in Life-Threatening Illnesses: Azidothymidine (AZT) for the Treatment of AIDS, 145

EXPERIMENTAL DESIGN
Delays in the Drug Approval Process: Recent Trends, 31
Early Termination of Clinical Trials, 83

FACTORIAL DESIGN
Factorial Design: An Approach to the Assessment of Therapeutic Drug Interactions in Clinical Trials, 215

FDA
Advisory Committees and the Drug Approval Process, 15
Carcinogenic Potential of Marketed Drugs, 141

FLURBIPROFEN
Comparative Comfort of Flurbiprofen Solution and Indomethacin Suspension Eyedrops, 233

HEPATITIS
Use of the Lognormal Distribution to Study the Time of Occurrence of Drug-Induced Diseases, 101

HYDROCHLOROTHIAZIDE
Factorial Design: An Approach to the Assessment of Therapeutic Drug Interactions in Clinical Trials, 215

INDOMETHACIN
Comparative Comfort of Flurbiprofen Solution and Indomethacin Suspension Eyedrops, 233

INTERSTITIAL NEPHRITIS
Use of the Lognormal Distribution to Study the Time of Occurrence of Drug-Induced Diseases, 101

LIFE-THREATENING ILLNESSES
Ethical Dilemma of Placebo-Controlled Trials in Life-Threatening Illnesses: Azidothymidine (AZT) for the Treatment of AIDS, 145

THE LIGHTER SIDE
Negotiating Budgets: Lessons from Mexico, 207
You, Too, Can Write an Abstract, 253

PHARMACEUTICAL LIABILITY LITIGATION
Epidemiology in Pharmaceutical Liability Litigation: Sword, Shield, or Booby Trap? 79

PHARMACEUTICAL STAFFING
Pharmaceutical Staffing Project: Data Summary, 241

PHARMACOEPIDEMIOLOGY
A Giant Step for Pharmacoepidemiology, 65
Pharmacoepidemiology: Is Ignorance Bliss? 67
Pharmacoepidemiology, FDA, and Million Dollar Verdicts, 75
Integrating Pharmacoepidemiolgy into the Design and Conduct of Clinical Trials, 161
Pharmacoepidemiology: A Call for Action, 179

PINACIDIL
Factorial Design: An Approach to the Assessment of Therapeutic Drug Interactions in Clinical Trials, 215

PLACEBO CONTROLS
Ethical Dilemma of Placebo-Controlled Trials in Life-Threatening Illnesses: Azidothymidine (AZT) for the Treatment of AIDS, 145

POSTMARKETING DRUG SURVEILLANCE
Integrating Pharmacoepidemiology into the Design and Conduct of Clinical Trials, 161

QUALITY OF LIFE
Delays in the Drug Approval Process: Recent Trends, 31

RANDOMIZED CLINICAL CONTROLS
Ethical Dilemma of Placebo-Controlled Trials in Life-Threatening Illnesses: Azidothymidine (AZT) for the Treatment of AIDS, 145

REGULATORY AGENCIES
Advisory Committees and the Drug Approval Process, 15

RESPONSE SURFACE METHODOLOGY
Factorial Design: An Approach to the Assessment of Therapeutic Drug Interactions in Clinical Trials, 215

TISSUE PLASMINOGEN ACTIVATOR (TPA)
The TPA Controversy: Letter and Commentaries, 3

TPA
The TPA Controversy: Letter and Commentaries, 3

TRIAL MANAGEMENT
Electronic Drug Accountability: A Trial Management Tool, 169

RANDOMIZED CLINICAL TRIAL
When and at What Stage Should a New Therapy for AIDS Be Evaluated in a Randomized Clinical Trial, 47
Ethical Dilemma of Placebo-Controlled Trials in Life-Threatening Illnesses: Azidothymidine (AZT) for the Treatment of AIDS, 145

REGULATORY AGENCIES
Advisory Committees and the Drug Approval Process, 15

RESEARCH DESIGN
Ethical Dilemma of Placebo-Controlled Trials in Life-Threatening Illnesses: Azidothymidine (AZT) for the Treatment of AIDS, 145

RISK-BENEFIT/ENDPOINT DETERMINATIONS
Delays in the Drug Approval Process: Recent Trends, 31

SPAIN
Drug Development in Spain: Towards a Brighter Future? 245

STAFFING
Pharmaceutical Staffing Project: Data Summary, 241

STEROIDS
Steroids, Diabetes, Analgesics, and the Risk of Cataract: Lessons from the Epidemiology of Cataract Extraction, 227

TOPICAL NONSTEROIDAL ANTIINFLAMMATORY DRUGS
Comparative Comfort of Flurbiprofen Solution and Indomethacin Suspension Eyedrops, 233

TRIAL MANAGEMENT
Electronic Drug Accountability: A Trial Management Tool, 169

VAGINAL NEOPLASMS
Use of the Lognormal Distribution to Study the Time of Occurrence of Drug-Induced Diseases, 101

VANCOMYCIN
Commentary on "Serum Concentrations and Adverse Effects of Vancomycin in Pediatric Patients" by Milap Nahata and Jacob Kammer, *Journal of Clinical Research and Drug Development* 1:307–312, 53